Biosimilars have been shown to be 15%–35% lower in cost than the reference product. The first Humira biosimilar is expected to hit the market in January 2023 with 6 months exclusivity.
Tag: Pharmacy Solutions
Pharmacy Benefit Manager (PBM) Data Load Re-Engineering
$230M Medical Benefit Drug Spend Reviewed; 6% Annual Cost Savings Identified
Medicaid Conversations: Pharmacy Carve-outs and 340B
Challenge to Traditional Chain Drug Retailers is Evident
